ArticleFrontiers in pharmacology2024

Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer.

Yongkuan Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.